Acute promyelocytic leukemia: Current strategies for the treatment of newly diagnosed disease

Clinical Advances in Hematology and Oncology

Volumn 3, Issue 5, 2005, Pages

  Sirulnik, L Andres ^a   Stone, Richard M ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Acute promyelocytic leukemia; All trans retinoic acid; Anthracylines; Cytarabine

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTIFIBRINOLYTIC AGENT; ANTINEOPLASTIC AGENT; ARSENIC TRIOXIDE; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; FLT3 LIGAND; GEMTUZUMAB OZOGAMICIN; HEPARIN; HISTONE DEACETYLASE INHIBITOR; IDARUBICIN; MERCAPTOPURINE; METHOTREXATE; METHYLTRANSFERASE INHIBITOR; MONOCLONAL ANTIBODY; PROTEIN KINASE INHIBITOR; RETINOIC ACID; RETINOIC ACID RECEPTOR ALPHA;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; ANTINEOPLASTIC ACTIVITY; BLOOD CLOTTING DISORDER; BODY WEIGHT DISORDER; BONE MARROW; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CELL DIFFERENTIATION; CLINICAL TRIAL; DRUG BIOAVAILABILITY; DRUG MECHANISM; DRUG RESPONSE; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DYSPNEA; FEVER; GRANULOCYTE; HUMAN; HYPOTENSION; KIDNEY FAILURE; LEUKOCYTOSIS; LUNG INFILTRATE; MAINTENANCE THERAPY; MEDICAL DECISION MAKING; PERICARDIAL EFFUSION; PHYSICIAN; PLEURA EFFUSION; PRACTICE GUIDELINE; PROMYELOCYTE; PROMYELOCYTIC LEUKEMIA; RETINOIC ACID SYNDROME; REVIEW; TREATMENT OUTCOME; TREATMENT PLANNING; WEIGHT GAIN;

ANTINEOPLASTIC AGENTS; HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; PRACTICE GUIDELINES; REMISSION INDUCTION;

EID: 25844482027     PISSN: 15430790     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (69)

1. Hillestad LK. Acute promyelocytic leukemia. Acta Med Scand. 1957;159(3):189-194.
2. Mandelli F, Avvisati G, Lo Coco F. Advances in the understanding and management of acute promyelocytic leukemia. Rev Clin Exp Hematol. 2002;6(1):60-71; discussion 86-67.
3. Rowley J, Golumb H, Dougherty C. 15/17 translocation a consistant chromsomal change in acute promyelocytic leukemia. Lancet. 1977;1(549-550).
4. de Thé H, Chomienne C, Lanotte M, Degos L, Dejean A. The t(15;17) translocation of acute promyleocytic leukemia fuses the retinoic acid receptor a gene to a novel transcribed locus. Nature. 1990;347(558):1990.
5. Kakizuka A, Miller WJ, Umesono K, et al. Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RAR alpha with a novel putative transcription factor, PML. Cell. 1991;66(4):663-674.
6. Sirulnik A, Melnick A, Zelent A, Licht JD. Molecular pathogenesis of acute promyelocytic leukaemia and APL variants. Best Pract Res Clin Haematol. 2003;16(3):387-408.
7. Melnick A, Licht JD. Deconstructing a disease: RARalpha, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia. Blood. 1999;93(10):3167-3215.
8. Degos L. The history of acute promyelocytic leukaemia. Br J Haematol. 2003;122(4):539-553.
9. Bennett JM, Catovsky D, Daniel MT, et al. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. Ann Intern Med. 1985;103(4):620-625.
10. McKenna RW, Parkin J, Bloomfield CD, Sundberg RD, Brunning RD. Acute promyelocytic leukaemia: a study of 39 cases with identification of a hyperbasophilic microgranular variant. Br J Haematol. 1982;50(2):201-214.
11. Golomb HM, Rowley JD, Vardiman JW, Testa JR, Butler A. "Microgranular" acute promyelocytic leukemia: a distinct clinical, ultrastructural, and cytogenetic entity. Blood. 1980;55(2):253-259.
12. Tallman MS, Andersen JW, Schiffer CA, et al. All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocol. Blood. 2002;100(13):4298-4302.
13. De Rossi G, Avvisati G, Coluzzi S, et al. Immunological definition of acute promyelocytic leukemia (FAB M3): a study of 39 cases. Eur J Haematol. 1990;45(3):168-171.
14. Paietta E, Andersen J, Gallagher R, et al. The immunophenotype of acute promyelocytic leukemia (APL): an ECOG study. Leukemia. 1994;8(7):1108-1112.
15. De Botton S, Chevret S, Sanz M, et al. Additional chromosomal abnormalities in patients with acute promyelocytic leukaemia (APL) do not confer poor prognosis: results of APL 93 trial. Br J Haematol. 2000;111(3):801-806.
16. Hernandez JM, Martin G, Gutierrez NC, et al. Additional cytogenetic changes do not influence the outcome of patients with newly diagnosed acute promyelocytic leukemia treated with an ATRA plus anthracyclin based protocol. A report of the Spanish group PETHEMA. Haematologica. 2001;86(8):807-813.
17. Pulsoni A, Pagano L, Lo Coco F, et al. Clinicobiological features and outcome of acute promyelocytic leukemia occurring as a second tumor: the GIMEMA experience. Blood. 2002;100(6):1972-1976.
18. Beaumont M, Sanz M, Carli PM, et al. Therapy-related acute promyelocytic leukemia. J Clin Oncol. 2003;21(11):2123-2137.
19. Falanga A, Rickles FR. Pathogenesis and management of the bleeding diathesis in acute promyelocytic leukaemia. Best Pract Res Clin Haematol. 2003;16(3):463-482.
20. Sanz MA, Lo Coco F, Martin G, et al. Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups. Blood. 2000;96(4):1247-1253.
21. Latagliata R, Petti MC, Fenu S, et al. Therapy-related myelodysplastic syndrome-acute myelogenous leukemia in patients treated for acute promyelocytic leukemia: an emerging problem. Blood. 2002;99(3):822-824.
22. Lobe I, Rigal-Huguet F, Vekhoff A, et al. Myelodysplastic syndrome after acute promyelocytic leukemia: the European APL group experience. Leukemia. 2003;17(8):1600-1604.
23. Rodeghiero F, Avvisati G, Castaman G, Barbui T, Mandelli F. Early deaths and anti-hemorrhagic treatments in acute promyelocytic leukemia. A GIMEMA retrospective study in 268 consecutive patients. Blood. 1990;75(11):2112-2117.
24. Bassan R, Battista R, Viero P, et al. Short-term treatment for adult hypergranular and microgranular acute promyelocytic leukemia. Leukemia. 1995;9(2):238-243.
25. Bernard J, Weil M, Boiron M, Jacquillat C, Flandrin G, Gemon MF. Acute promyelocytic leukemia: results of treatment by daunorubicin. Blood. 1973;41(4):489-496.
26. Marty M, Ganem G, Fischer J, et al. [Acute promyelocytic leukemia: retrospective study of 119 patients treated with daunorubicin]. Nouv Rev Fr Hematol. 1984;26(6):371-378.
27. Head D, Kopecky KJ, Weick J, et al. Effect of aggressive daunomycin therapy on survival in acute promyelocytic leukemia. Blood. 1995;86(5):1717-1728.
28. Miyachi H, Takemura Y, Yonekura S, et al. MDR1 (multidrug resistance) gene expression in adult acute leukemia: correlations with blast phenotype. Int J Hematol. 1993;57(1):31-37.
29. Paietta E, Andersen J, Racevskis J, et al. Significantly lower P-glycoprotein expression in acute promyelocytic leukemia than in other types of acute myeloid leukemia: immunological, molecular and functional analyses. Leukemia. 1994;8(6):968-973.
30. Fenaux P, Le Deley MC, Castaigne S, et al. Effect of all transretinoic acid in newly diagnosed acute promyelocytic leukemia. Results of a multicenter randomized trial. European APL 91 Group. Blood. 1993;82(11):3241-3249.
31. Fenaux P, Chevret S, Guerci A. et al. Long-term follow-up confirms the benefit of all-trans retinoic acid in acute promyelocytic leukemia. European APL group. Leukemia. 2000;14(8):1371-1377.
32. Fenaux P, Chastang C, Chevret S, et al. A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. The European APL Group. Blood. 1999;94(4):1192-1200.
33. Tallman MS, Andersen JW, Schiffer CA, et al. All-trans-retinoic acid in acute promyelocytic leukemia [see comments]. N Engl J Med. 1997;337(15):1021-1028.
34. Barbui T, Finazzi G, Falanga A. The impact of all-trans-retinoic acid on the coagulopathy of acute promyelocytic leukemia. Blood. 1998;91(9):3093-3102.
35. Frankel SR, Eardley A, Lauwers G, Weiss M,Warrell RP, Jr. The "retinoic acid syndrome" in acute promyelocytic leukemia. Ann Intern Med. 1992;117(4):292-296.
36. Fenaux P, De Botton S. Retinoic acid syndrome. Recognition, prevention and management. Drug Saf. 1998;18(4):273-279.
37. Larson RS, Tallman MS. Retinoic acid syndrome: manifestations, pathogenesis, and treatment. Best Pract Res Clin Haematol. 2003;16(3):453-461.
38. Estey E, Thall PF, Pierce S, Kantarjian H, Keating M. Treatment of newly diagnosed acute promyelocytic leukemia without cytarabine. J Clin Oncol. 1997;15(2):483-490.
39. Avvisati G, Perti MC, Lo-Coco F, et al. Induction therapy with idarubicin alone significantly influences event-free survival duration in patients with newly diagnosed hypergranular acute promyelocytic leukemia: final results of the GIMEMA randomized study LAP 0389 with 7 years of minimal follow-up. Blood. 2002;100(9):3141-3146.
40. Sanz MA, Martin G, Gonzalez M, et al. Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: a multicenter study by the PETHEMA group. Blood. 2004;103(4):1237-1243.
41. Burry LD, Seki JT. CNS relapses of acute promyelocytic leukemia after all-trans retinoic acid. Ann Pharmacother. 2002;36(12):1900-1906.
42. Estey EH, Giles FJ, Beran M, et al. Experience with gemtuzumab ozogamycin ("mylotarg") and all-trans retinoic acid in untreated acute promyelocytic leukemia. Blood. 2002;99(11):4222-4224.
43. Estey EH, Faderl S, Giles F, et al. All-Trans Retinoic Acid (ATRA) + Arsenic Trioxide (ATO) to Minimize or Eliminate Chemotherapy in Untreated APL. Blood. 2003;102(11). Abstract 2283.
44. Shi Z, Shen Z, Fang J, et al. Induction/Maintenance with ATRA/As2O3 Combination Yields a High Quality Clinical/Molecular Remission and Disease-Free Survival in Newly Diagnosed Patients with Acute Promyelocytic Leukemia. Blood. 2003;102(11)Abstract 486.
45. Jiang Y, Kantarjian HM, Faderl SH, Cortes J, Koller C, Estey EH. Follow-Up of Gemtuzumab Ozogamycin (Mylotarg) and All-trans Retinoic Acid in Untreated Acute Promyelocytic Leukemia. Blood. 2003;102(11):Abstract 2284
46. Estey EH, Garcia-Manero G, Ferrajoli A, Faderl S, Verstovsek S, Kantarjian H. Use of All-Transretinoic Acid (ATRA) + Arsenic Trioxide (ATO) To Eliminate or Minimize Use of Chemotherapy (CT) in Untreated Acute Promyelocytic Leukemia (APL). Blood. 2004;104(11):Abstract 393.
47. Ghavamzadeh A, Alimoghaddam K, Ghaffari H, et al. Treatment of New Cases of Acute Promyelocytic Leukaemia by Arsenic Trioxide. Blood. 2004;104(11): Abstract 396.
48. Liu YF, Shen ZX, Hu J, et al. Clinical Observation on the Efficacy of All-Trans Retinoic Acid (ATRA) Combined with Arsenic Trioxide (As2O3) in Newly Diagnosed Acute Promyelocytic Leukemia (APL). Blood. 2004;104(11):Abstract 888
49. 3) in the Treatment of Patients with Newly Diagnosed Acute Promyelocytic Leukemia (APML) - Toxicity and Outcome. Blood. 2004;104(11): Abstract 899.
50. 3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci U S A. 2004;101(15):5328-5335.
51. Burnett AK, Grimwade D, Solomon E, Wheatley K, Goldstone AH. Presenting white blood cell count and kinetics of molecular remission predict prognosis in acute promyelocytic leukemia treated with all-trans retinoic acid: result of the Randomized MRC Trial. Blood. 1999;93(12):4131-4143.
52. Mandelli F, Diverio D, Avvisati G, et al. Molecular remission in PML/RAR alpha-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy. Gruppo Italiano-Malattie Ematologiche Maligne dell'Adulto and Associazione Italiana di Ematologia ed Oncologia Pediatrica Cooperative Groups. Blood. 1997;90(3):1014-1021.
53. Sanz AM, Martin G, Rayon C, et al. A modified AIDA protocol with anthracycline-based consolidation results in high antileukemic efficacy and reduced toxicity in newly diagnosed PML/RARalpha-positive acute promyelocytic leukemia. PETHEMA group. Blood. 1999;94(9):3015-3021.
54. Gallagher RE, Yeap BY, Bi W, et al. Quantitative real-time RT-PCR analysis of PML-RAR alpha mRNA in acute promyelocytic leukemia: assessment of prognostic significance in adult patients from intergroup protocol 0129. Blood. 2003;101(7):2521-2528.
55. Grimwade D, Lo Coco F. Acute promyelocytic leukemia: a model for the role of molecular diagnosis and residual disease monitoring in directing treatment approach in acute myeloid leukemia. Leukemia. 2002;16(10):1959-1973.
56. Lo-Coco F, Breccia M, Diverio D. The importance of molecular monitoring in acute promyelocytic leukaemia. Best Pract Res Clin Haematol. 2003;16(3):503-520.
57. Lo Coco F, Avvisati G, Vignetti M, et al. Front-Line Treatment of Acute Promyelocytic Leukemia with AIDA Induction Followed by Risk-Adapted Consolidation: Results of the AIDA-2000 Trial of the Italian GIMEMA Group. Blood. 2004;104(11):Absract 392.
58. Ades L, Raffoux E, Chevret S, et al. Is AraC Required in the Treatment of Newly Diagnosed APL? Results of a Randomized Trial (APL 2000). Blood. 2004;104(11):Abstract 391.
59. Muindi J, Frankel SR, Miller WH, Jr., et al. Continuous treatment with all-trans retinoic acid causes a progressive reduction in plasma drug concentrations: implications for relapse and retinoid "resistance" in patients with acute promyelocytic leukemia. Blood. 1992;79(2):299-303.
60. Atiba JO, Manzardo AM, Thiruvengadam R, Schell MJ, Meyskens FL, Jr. Restoration of oral all-trans retinoic acid bioavailability after a brief drug holiday. Am J Ther. 1997;4(4):134-140.
61. Adamson PC, Reaman G, Finklestein JZ, et al. Phase I trial and pharmacokinetic study of all-trans-retinoic acid administered on an intermittent schedule in combination with interferon-alpha2a in pediatric patients with refractory cancer. J Clin Oncol. 1997;15(11):3330-3337.
62. Visani G, Buonamici S, Malagola M, et al. Pulsed ATRA as single therapy restores long-term remission in PML-RARalpha-positive acute promyelocytic leukemia patients: real time quantification of minimal residual disease. A pilot study. Leukemia. 2001;15(11):1696-1700.
63. Avvisati G, Petti MC, Lo Coco F, et al. AIDA: The Italian Way of Treating Acute Promyelocytic Leukemia (APL), Final Act. Blood. 2003;102(11):ASH Meeting Abstract 487.
64. Gilliland DG, Griffin JD. Role of FLT3 in leukemia. Curr Opin Hematol. 2002;9(4):274-281.
65. Chen Z, Brand NJ, Chen A, et al. Fusion between a novel Kruppel-like zinc finger gene and the retinoic acid receptor-alpha locus due to a variant t(11;17) translocation associated with acute promyelocytic leukaemia. Embo J. Mar 1993;12(3):1161-1167.
66. Redner RL, Rush EA, Faas S, Rudert WA, Corey SJ. The t(5;17) variant of acute promyelocytic leukemia expresses a nucleophosmin-retinoic acid receptor fusion. Blood. 1996;87(3):882-886.
67. Wells RA, Catzavelos C, Kamel-Reid S. Fusion of retinoic acid receptor alpha to NuMA, the nuclear mitotic apparatus protein, by a variant translocation in acute promyelocytic leukaemia. Nat Genet. Sep 1997;17(1):109-113.
68. Arnould C, Philippe C, Bourdon V, Gregoire MJ, Berger R, Jonveaux P. The signal transducer and activator of transcription STAT5b gene is a new partner of retinoic acid receptor alpha in acute promyelocytic-like leukaemia. Hum Mol Genet. 1999;8(9):1741-1749.
69. Lowenberg B, Griffin JD, Tallman MS. Acute myeloid leukemia and acute promyelocytic leukemia. Hematology (Am Soc Hematol Educ Program). 2003:82-101.